Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology Lyon, France & Duisburg, Germany, October 21, 2021 Mablink Bioscience S.A.S. a …
On October 14, during the MATWIN board meeting, Mablink’s COO Valérie Attuil was pitching in front of a panel of investors as part of the 2nd Oncology Upward Investment event. …
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
Mablink receives the support of the Canceropole CLARA to push forward the development of its ADC platform
Mablink receives the iLab 2019 award in the presence of French Minister of Higher Education, Research and Innovation, Mrs Frédérique Vidal, and Bpifrance, at the innovation awards ceremony in Paris.
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.
With more than 700 participants last April 4th/5th, the Auvergne-Rhône-Alpes Cancer Research Forum is one of the most federating events. During this event took place the Research2Business (R2B) Oncology Meeting …
French Tech Seed labeled company. Our company has recently been granted with the French Tech Seed label which rewards DeepTech projects lead by young dynamic companies. Our highly potent technology …
